Marty Makary out as FDA chief
He also took steps to reduce animal testing. </li></ul><p><strong>But Makary remained</strong> a magnet for controversy. Indeed, under his tenure the FDA approved a generic version.</li><li>Under Makary's leadership, the FDA also <a href="https://www.axios.com/2026/03/03/fda-rare-drug-diseases-critics" target="_blank">drew controversy</a> for rejecting certain rare disease drugs. Biologics division chief Vinay Prasad, who has also since left the agency, was at the center of those decisions as...
Covering href, Reporting on healthcare developments, this article provides evidence-based insights. High keyword density but difficult to read; creates an SEO-focused content impression. Notably, a data-rich piece: 1 citation(s), 0 entities, 30 key terms. On the other hand, our algorithmic assessment detects a strongly left-leaning orientation in this report (score: -100). The analytical profile of this article: moderate credibility, negligible information accuracy risk, and negligible propagand
This health report, covering marty, addresses topics impacting public health and well-being. High keyword density but difficult to read; creates an SEO-focused content impression. According to our assessment, a data-rich piece: 1 citation(s), 0 entities, 30 key terms. Notably, NLP credibility score is moderate (56), with the content referencing 0 named source(s).
Additionally, the language patterns in this article reflect a strongly left-leaning approach (-100). Furthermore, our grammar assessment is excellent (80/100); overall writing quality is fully meets. Notably, the text structure requires a very difficult to read reading level (avg sentence length: 16 words).
Final assessment: credibility moderate, misinformation negligible, propaganda negligible; content should be read with this profile in mind.